The Latest News and Notes, plus Conversation with Richard L. Lindstrom, MD

ByJohn A. Hovanesian, MD, FACS

ByJames Mazzo

ByRichard L. Lindstrom, MD

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.

Welcome to the Eyeluminaries podcast :00
OTF Meeting 01:41
Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04
Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42
The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21
Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24
Best of the year award – Pegcetacoplan 6:49
Near miss award – Beovu (brolucizumab) 8:08
Awful award – Byooviz (ranibizumab-nuna) 8:45
Guest welcome 9:40
Richard L. Lindstrom, MD, introduction 10:31
FDA grants fast track designation for retinitis pigmentosa treatment 10:36
EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14
Amazon launches discount prescription drug service 17:46
Interview with Lindstrom 21:42
What is the biggest innovation in ophthalmology in your career? 22:40
What is coming in the next 10 years? 25:24
What is out there that will get in the way of innovation? 26:54
What advice would you give to residents? 28:35
What advice would you give to entrepreneurs? 30:16
What story can you share about one historical figure in ophthalmology? 31:59
Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14
Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29
Thanks for listening 36:53

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO.

Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery.

We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian.

Published by:

Sources/Disclosures

Collapse

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.

Read more

The Latest News and Notes, plus Conversation with Richard L. Lindstrom, MD

Eyeluminaries

Related Content